Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INOSARS in mild COVID-19
NCT04514302Phase 1Completed
- Sponsor
- TecSalud
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anti SARS-CoV-2 equine hyperimmune serum in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by TecSalud. Primary endpoints: Average change from baseline in viral load at 28 days, Proportion of patients with undetectable viral load at 28 days and 1 more. Started Dec 2021; status: completed.
02
Drugs
anti SARS-CoV-2 equine hyperimmune serum
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04514302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514302.